Mirador Biomedical Inc.
Reducing risk in central venous access
This article was originally published in Start Up
During insertion of central venous catheters, physicians may unintentionally advance into an artery rather than the desired vein, an error that can cause serious complications, even death. Mirador Biomedical Inc. aims to improve the safety of central venous access with its Compass platform, battery-powered, pressure-measurement devices that can rapidly detect the difference in pressures between arteries and veins.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.